PICO Advisory Sub-Committee - Applications Considered
1495 - Somatic tumour gene panel test
1512 - Apolipoprotein B testing for high risk cardiovascular disease risk assessment
1518 - Endoscopic non-contact (side firing) visual laser ablation of the prostate (VLAP) for benign prostatic hyperplasia (BPH)
1519 - Tisagenlecleucel (CTL019, chimeric antigen receptor T cell: CAR-T therapy) for treatment of refractory CD19-positive leukaemia and lymphoma
1522 - PD-L1 (Programmed Death-Ligand 1) immunohistochemistry testing for access to pembrolizumab as first-line therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma
1524 - Expanding the BRAF testing MBS item to include patients with resectable Stage III melanoma (co-dependent)
1525 - Low dose rate (LDR) brachytherapy for intermediate and high-risk prostate cancer
1526 - Somatic tumour gene testing for the diagnosis of Diffuse Large B Cell Lymphoma, Multiple Myeloma and Non-Hodgkin Lymphoma Subtypes
1527 - Somatic tumour gene testing for the diagnosis of Gliomas, Gliobastomas, and Soft Tissue and Bone Tumours
1528 - Somatic tumour gene testing for the diagnosis of renal cell carnicoma, hydatidiform moles, granulosa cell ovarian tumour, salivary gland tumours, and secretory carcinoma of the breast
1530 - Purified human alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase inhibitor deficiency, leading to chronic obstructive pulmonary disease (COPD)